Business Context and Reporting Period
This Form 6-K filing by NervGen Pharma Corp. covers the month of February 2026, specifically reporting on corporate governance changes effective February 9, 2026. The company is a foreign private issuer based in Vancouver, British Columbia, Canada.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and employment terms rather than financial performance.
Material Changes
The primary material change is the appointment of Dr. Adam Rogers as Chief Executive Officer and President, effective immediately. Dr. Rogers transitions from his role as Interim CEO (held since July 17, 2025) and continues to serve as Chairperson of the Board.
Guidance, Outlook, and Management Commentary
Employment Terms and Compensation:
- Base Salary: $350,000 annualized.
- Annual Bonus: Eligible for up to 30.0% of base salary, determined by the Board.
- Stock Options (Time-Based): Grant of 717,891 options.
- 614,799 options at $5.06/share (10-year term).
- 103,092 options at $5.57/share (5-year term).
- Vesting: 25% on the first anniversary (Cliff Date), with the remaining 75% vesting monthly over the subsequent 36 months.
- Stock Options (Performance-Based): Agreement to grant an additional 1,146,108 options subject to future performance conditions.
- Equity Grants: Agreement to grant 37,784 fully vested common shares and 617,135 performance-based restricted stock units (subject to plan amendments).
Severance Provisions:
- Termination for Cause: Payment of the lesser of four weeks' base salary or remaining term salary; COBRA coverage for up to 4 weeks.
- Termination Without Cause/Good Reason: Severance benefit of 6 months' base salary plus 2 months for each completed year of service (capped at 12 months total); acceleration of equity vesting for the 12 months following termination; COBRA coverage for up to 12 months.
- Change of Control: If termination occurs within 3 months prior to or 12 months following a change of control, full acceleration of unvested equity awards applies.
Investor Verification Checklist
- Verify the exact vesting schedule and performance conditions for the 1,146,108 performance-based options and 617,135 RSUs, as these are to be determined subsequently.
- Confirm the status of the Stock Option Plan amendment required to grant the additional equity awards.
- Review the full text of the Employment Agreement (Exhibit 10.1) for complete legal terms regarding termination and severance.
- Assess the impact of the new CEO's compensation package on future cash burn and dilution, given the company's clinical-stage status.